GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs Inc. (NASDAQ:GOVX) was the target of a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 367,575 shares, an increase of 101.6% from the August 15th total of 182,364 shares. Approximately 5.0% of the company’s shares are short sold. Based on an average daily volume of 2,024,690 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

GOVX has been the topic of a number of research reports. Noble Financial reaffirmed an “outperform” rating on shares of GeoVax Labs in a research note on Tuesday. Wall Street Zen upgraded shares of GeoVax Labs from a “sell” rating to a “hold” rating in a report on Sunday, June 21st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $150.00.

GeoVax Labs Stock Down 2.7%

Shares of NASDAQ:GOVX traded down $0.01 during midday trading on Tuesday, reaching $0.42. The company’s stock had a trading volume of 403,803 shares, compared to its average volume of 1,287,708. The firm has a 50 day moving average of $0.73 and a 200-day moving average of $1.26. The firm has a market capitalization of $3.08 million, a P/E ratio of -0.04 and a beta of 3.66. GeoVax Labs has a 12-month low of $0.41 and a 12-month high of $17.74.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Monday, July 27th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.16) by $1.19. On average, research analysts predict that GeoVax Labs will post -4.94 EPS for the current year.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.